There is an increasing demand for nutritional ingredients and products in the market today as consumers are looking to support their health. Supplements that address digestive health and immune function are just two of the top priorities, particularly in the China as there is a growing need for human probiotics.

To cater to the Chinese market, ADM will partner with Qingdao Vland Biotech Group Co. Ltd, producer of enzymes and probiotics. This joint venture, which is set to launch in the first half of 2022, will bring forth the expertise and experience from both companies to introduce innovative solutions in gut health.  

“This exciting new joint venture represents the latest expansion in our full-scale global health & wellness business, which is helping propel growth across our entire human and animal nutrition portfolio, and creating value for ADM and customers alike,” said Vince Macciocchi, president of ADM’s Nutrition business. “We’re excited to partner with Vland to help meet the needs of consumers who are becoming increasingly aware of the strong linkage between health of the gut microbiome and their overall health. Retail demand for probiotics in China is estimated to be $1 billion in 2022, with annual growth of more than 9 percent, and we believe this new venture – powered by the expertise and experience of both ADM and Vland – is perfectly positioned to play a leading role in meeting that demand.”

“Vland is quite excited to partner with ADM to explore the promising market of human probiotics,” said Aron Chen, CEO of Vland. “We believe this strong partnership between Vland and ADM – powered by the technology, brand and sales channels of both parties – will be perfectly positioned to expand production and meet demand for high-quality human probiotics in China and for global customers.”